Wedbush Analysts Cut Earnings Estimates for Zenas BioPharma

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Analysts at Wedbush lowered their Q3 2025 earnings estimates for Zenas BioPharma in a research report issued to clients and investors on Tuesday, August 12th. Wedbush analyst M. Fan now expects that the company will post earnings per share of ($1.33) for the quarter, down from their prior forecast of ($1.04). Wedbush has a “Outperform” rating and a $35.00 price target on the stock. Wedbush also issued estimates for Zenas BioPharma’s Q4 2025 earnings at ($1.13) EPS, FY2025 earnings at ($4.51) EPS, Q1 2026 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.17) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($4.41) EPS, FY2028 earnings at ($3.02) EPS and FY2029 earnings at ($1.20) EPS.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.23).

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Zenas BioPharma in a research note on Friday, May 16th.

Zenas BioPharma Price Performance

ZBIO stock opened at $16.82 on Friday. The company has a market capitalization of $708.29 million and a PE ratio of -4.74. The business has a 50-day moving average of $12.74. Zenas BioPharma has a 12 month low of $5.83 and a 12 month high of $26.25.

Hedge Funds Weigh In On Zenas BioPharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund bought a new position in Zenas BioPharma in the 1st quarter valued at approximately $49,000. Jefferies Financial Group Inc. bought a new position in Zenas BioPharma in the 1st quarter valued at approximately $348,000. Geode Capital Management LLC raised its holdings in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares during the last quarter. Rhumbline Advisers raised its holdings in Zenas BioPharma by 71.3% in the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after buying an additional 8,207 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after buying an additional 3,412 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.